

# Molecular In My Pocket™ ...

## ONCOLOGY: Pediatric Solid Tumors

Prepared by the Association for Molecular Pathology Training and Education Committee

Tissue Type	Tumor Type	Gene/Biomarker	Alteration	Significance	Primary Assays
<b>Thyroid</b>	Papillary Thyroid Carcinoma	<i>BRAF</i>	sequence variant (30%, mostly p.V600E), fusion (10%)	diagnosis, treatment	IHC (BRAF V600E), NGS (DNA, RNA), ddPCR
		<i>RET</i> (30%)	fusion	diagnosis, treatment	NGS (DNA, RNA)
		<i>NTRK1, NTRK3</i> (10%)	fusion	diagnosis, treatment	IHC (pan-TRK; screening), NGS (DNA, RNA)
		<i>ALK</i> (5%)	fusion	diagnosis, treatment	IHC (ALK; screening), NGS (DNA, RNA), FISH
		<i>HRAS, NRAS</i> (<5%)	sequence variant	diagnosis	NGS (DNA)
		<i>DICER1</i> (<10%)	sequence variant	familial cancer risk	NGS (DNA)
		<i>TERT</i>	sequence variant	diagnosis, prognosis	NGS (DNA)
		<i>TP53</i>	sequence variant	diagnosis, prognosis	NGS (DNA)
	Cribriform Morular Thyroid Carcinoma	<i>APC</i>	loss-of-function variant	diagnosis, familial cancer risk	NGS (DNA)
		<i>CTNNB1</i>	sequence variant, intragenic deletion	diagnosis	NGS (DNA)
	Follicular Thyroid Carcinoma	<i>PPARG</i>	fusion (typically with <i>PAX8</i> )	diagnosis	NGS (DNA, RNA)
		<i>HRAS, KRAS, NRAS</i>	sequence variant	diagnosis	NGS (DNA)
	*With Multiple Adenomas/Adenomatous Nodules*	<i>PTEN</i>	sequence variant	diagnosis, familial cancer risk	NGS (DNA)
Medullary Thyroid Carcinoma	<i>RET</i> (>95%)	sequence variant	diagnosis, familial cancer risk, treatment	NGS (DNA)	
Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP)	<i>HRAS, KRAS, NRAS</i>	sequence variant	diagnosis	NGS (DNA)	
<b>Lung</b>	Pleuropulmonary Blastoma	<i>DICER1</i>	loss-of-function sequence variant or deletion + hotspot sequence variant	diagnosis, familial cancer risk	NGS (DNA)
<b>GI</b>	Gastrointestinal Stromal Tumor	<i>SDHA, SDHB, SDHC, SDHD</i>	sequence variant, loss of protein expression	diagnosis, familial cancer risk	IHC (SDHB), NGS (DNA)
<b>Liver</b>	Hepatoblastoma	<i>CTNNB1</i> (90%)	activating sequence variant, deletion of exon 3	diagnosis (more common in hepatoblastoma than in hepatocellular carcinoma)	IHC (beta-catenin), NGS (DNA)
	Fibrolamellar Carcinoma	<i>DNAJB1::PRKACA</i>	fusion	diagnosis	FISH, NGS (DNA, RNA)
<b>Kidney</b>	Wilms Tumor	1q gain 1p/16q LOH	copy gain LOH	prognosis	CMA, NGS (DNA)
	Clear Cell Sarcoma of Kidney	<i>BCOR</i>	internal tandem duplication (ITD)	diagnosis	IHC (BCOR), NGS (DNA, RNA)
		<i>YWHAE</i>	fusion	diagnosis	NGS (DNA, RNA)
	Cellular Congenital Mesoblastic Nephroma	<i>NTRK3</i>	fusion (mostly <i>ETV6::NTRK3</i> )	diagnosis, treatment	FISH or RT-PCR for classic fusion; NGS (DNA, RNA) for classic or alternate fusions
Renal Cell Carcinoma with MiT Translocation	<i>TFE3</i> (>90%), <i>TFEB</i>	fusion	diagnosis	IHC (TFE3, TFEB), FISH, NGS (DNA, RNA)	

<b>Kidney</b> <i>(continued...)</i>	Metanephric Adenoma	<i>BRAF</i>	p.V600E, other exon 15 sequence variant	diagnosis	IHC (BRAF V600E), NGS (DNA), ddPCR
	Rhabdoid Tumor	<i>SMARCB1 (INI1; &gt;90%), SMARCA4 (BRG1)</i>	loss (sequence variant, deletion)	diagnosis, familial cancer risk	IHC (INI1, BRG1), CMA, NGS (DNA), MLPA
	Pediatric Cystic Nephroma	<i>DICER1</i>	loss-of-function sequence variant	diagnosis, familial cancer risk	NGS (DNA)
<b>Ovary</b>	Juvenile Granulosa Cell Tumor	<i>AKT1</i> (60%)	in-frame duplication, sequence variant	diagnosis	NGS (DNA)
		<i>GNAS</i> (30%)	sequence variant	diagnosis	NGS (DNA)
<b>Eye</b>	Retinoblastoma	<i>RB1</i>	inactivating mutation, loss, or LOH	diagnosis, familial cancer risk	MLPA, CMA, NGS (DNA)
<b>Neural Crest</b>	Paraganglioma	<i>SDHA, SDHB, SDHC, SDHD</i>	sequence variant, loss of protein expression	diagnosis, familial cancer risk	IHC (SDHB), NGS (DNA)
	Neuroblastoma	<i>MYCN</i>	amplification	prognosis	FISH, CMA, NGS (DNA)
		<i>ALK</i>	sequence variant, amplification	prognosis, treatment	NGS (DNA)
		<i>ATRX</i>	loss-of-function sequence variant	prognosis	NGS (DNA)
		1p/11q LOH	LOH	prognosis	CMA, NGS (DNA)
<b>Multi-system</b>	<i>DICER1</i> Syndrome	<i>DICER1</i>	loss-of-function sequence variant or deletion (germline)	diagnosis, familial cancer risk	NGS (DNA)
	Constitutional Mismatch Repair Deficiency Syndrome (CMMRD)	<i>MLH1, MSH2, PMS2, MSH6</i>	loss-of-function sequence variant or deletion (germline, biallelic)	diagnosis, familial cancer risk, treatment	IHC (MLH1, MSH2, PMS2, MSH6), NGS (DNA), MSI
	Gorlin Syndrome	<i>SUFU, PTCH1</i>	loss-of-function sequence variant, deletion/duplication (germline)	diagnosis, familial cancer risk	NGS (DNA), CMA, MLPA
	Multiple Endocrine Neoplasia (MEN) 2A/2B	<i>RET</i>	gain-of-function sequence variant (germline)	diagnosis, familial cancer risk	NGS (DNA)
	Li-Fraumeni Syndrome	<i>TP53</i>	loss-of-function sequence variant (germline)	diagnosis, familial cancer risk	NGS (DNA)

#### Abbreviations:

**CGH** Comparative Genomic Hybridization

**FISH** Fluorescent *in situ* Hybridization

**MLPA** Multiplex Ligation-dependent Probe Amplification

**PCR** Polymerase Chain Reaction

**CMA** Chromosomal Microarray Analysis

**IHC** Immunohistochemistry

**MSI** Microsatellite Instability

**RT-PCR** Reverse Transcription PCR

**ddPCR** Digital Droplet PCR

**LOH** Loss of Heterozygosity

**NGS** Next Generation Sequencing



“Molecular in My Pocket” reference cards are educational resources created by the Association of Molecular Pathology (AMP) for laboratory and other health care professionals. The content does not constitute medical or legal advice, and is not intended for use in the diagnosis or treatment of individual conditions. See [www.amp.org](http://www.amp.org) for the full “Limitations of Liability” statement. For more educational resources, see: [www.amp.org/AMPEducation](http://www.amp.org/AMPEducation)